Nanotechnology in ocular delivery: Current and future directions

Drugs of Today

Volumn 47, Issue 6, 2011, Pages 441-455

  Sultana, Yasmin ^a   Maurya, D P ^a   Iqbal, Z ^a   Aqil, M ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACICLOVIR; AMIKACIN; BETAMETHASONE; BETAXOLOL; BUDESONIDE; CARTEOLOL; CLORICROMEN; CYCLOPENTOLATE; CYCLOSPORIN A; DEXAMETHASONE; DICLOFENAC; DORZOLAMIDE; FLURBIPROFEN; GANCICLOVIR; GATIFLOXACIN; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; METHYLPREDNISOLONE; METIPRANOLOL; PILOCARPINE; PIROXICAM; PROGESTERONE; SULFONAMIDE; TIMOLOL; TRIAMCINOLONE; TROPICAMIDE; UNINDEXED DRUG; VERTEPORFIN;

BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED DRUG RELEASE; CORNEA EPITHELIUM; CYTOMEGALOVIRUS RETINITIS; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TRANSPORT; DRY EYE; ENCAPSULATION; EYE TOXICITY; GLAUCOMA; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; KERATOCONJUNCTIVITIS SICCA; MICROEMULSION; NANODEVICE; NANOEMULSION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; SUSPENSION; SUSTAINED DRUG RELEASE; UVEITIS;

ANIMALS; DENDRIMERS; DRUG DELIVERY SYSTEMS; EMULSIONS; EYE DISEASES; HUMANS; LIPOSOMES; NANOPARTICLES; NANOTECHNOLOGY;

EID: 80052762003     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.6.1549023     Document Type: Review

References (139)

1. Lee, V.H.L., Robinson, J.R. Mechanistic and quantitativeevaluation of pre-corneal pilocarpine disposition in albino rabbits. J Pharm Sci 1979, 68(6): 673-84.
2. Chrai, S.S., Robinson, J.R. Ocular evaluation of methylcellulose vehicle in albino rabbits. J Pharm Sci 1974, 63(8): 1218-23.
3. Worakul, N., Robinson, J.R. Ocular pharmacokinetics/pharmacodynamics. Eur J Pharm Biopharm 1997, 44(1): 71-83.
4. Barber, R.F., Shek, P.N. Liposomes as topical ocular drug delivery system. In: Pharmaceutical Particulate Carriers. A. Rolland (Ed.). Marcel Dekker: New York 1993, 1-20.
5. Patton, T.F., Robinson, J.R. Ocular evaluation of polyvinyl alcohol vehicle in rabbits. J Pharm Sci 1975, 64(8): 1312-6.
6. Saettone, M.F., Giannaccini, B., Teneggi, A., Savigni, P., Tellini, N. Vehicle effects on ophthalmic bioavailability - the influence of different polymers on the activity of pilocarpine in rabbit and man. J Pharm Pharmacol 1982, 34(7): 464-6.
7. Ravi Kumar, M.N. Nano and microparticles as controlled drug delivery devices. J Pharm Pharm Sci 2000, 3(2): 234-58.
8. Couvreur, P., Kante, B., Grislain, L., Roland, M., Speiser, P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. J Pharm Sci 1982, 71(7): 790-2.
9. Ellis-Behnke, R., Jonas, J.B. Redefining tissue engineering for nanomedicine in ophthalmology. Acta Ophthalmol 2011, 89(2): e108-14.
10. Beck, P., Kreuter, J., Reszka, R., Fichtner, I. Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. J Microencapsul 1993, 10(1): 101-14.
11. Kayser, O., Lemke, A., Hernandez-Trejo, N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol 2005, 6(1): 3-5.
12. Brigger, I., Dubernet, C., Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002, 54(5): 631-51.
13. Shenoy, D., Little, S., Langer, R., Amiji, M. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 2. In vivo distribution and tumor localization studies. Pharm Res 2005, 22(12): 2107-14.
14. Chan, C.C., Caspi, R.R., Ni, M., Leake, W.C., Wiggert, B., Chader, G.J., Nussenblatt, R.B. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun 1990, 3(3): 247-55.
15. Tosi, G., Costantino, L., Ruozi, B., Forni, F., Vandelli, M.A. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 2008, 5(2): 155-74.
16. Del Amo, E.M., Urtti, A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008, 13(3-4): 135-43.
17. Booth, B.A., Vidal Denham, L., Bouhanik, S., Jacob, J.T., Hill, J.M. Sustained-release ophthalmic drug delivery systems for treatment of macular disorders: present and future applications. Drugs Aging 2007, 24(7): 581-602.
18. Fattal, E., Bochot, A. Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 2006, 58(11): 1203-23.
19. Bourlais, C.L., Acar, L., Zia, H., Sado, P.A., Needham, T., Leverge, R. Ophthalmic drug delivery systems-recent advances. Prog Retin Eye Res 1998, 17(1): 33-58.
20. Sultana, Y., Jain, R., Aqil, M., Ali, A. Review of ocular drug delivery. Curr Drug Deliv 2006, 3(2): 207-17.
21. Vandervoort, J., Ludwig, A. Ocular drug delivery: nanomedicine applications. Nanomedicine (Lond) 2007, 2(1): 11-21.
22. Hamidi, M., Azadi, A., Rafiei, P. Hydrogel nanoparticles in drug delivery. Adv Drug Deliv Rev 2008, 60(15): 1638-49.
23. Sahoo, S.K., Dilnawaz, F., Krishnakumar, S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008, 13(3-4): 144-51.
24. Sahoo, S.K., Labhasetwar, V. Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003, 8(24): 1112-20.
25. Vasir, J.K., Reddy, M.K., Labhasetwar, V. Nanosystems in drug targeting: opportunities and challenges. Curr Nanosci 2005, 1: 47-64.
26. Ticho, U., Blumenthal, M., Zonis, S., Gal, A., Blank, I., Mazor, Z.W. A clinical trial with Piloplex-a new long-acting pilocarpine compound: preliminary report. Ann Ophthalmol 1979, 11(4): 555-61.
27. Barbu, E., Verestiuc, L., Nevell, T.G., Tsibouklis, J. Polymeric materials for ophthalmic drug delivery: trends and perspectives. J Mater Chem 2006, 16: 3439-43.
28. Ding, S. Recent development in ophthalmic drug delivery. Pharm Sci Tech Today 1998, 1: 328-35.
29. Zimmer, A., Kreuter, J. Microspheres and nanoparticles used in ocular delivery systems. Adv Drug Deliv Rev 1995, 16: 61-73.
30. Ludwig, A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005, 57(11): 1595-639.
31. Calvo, P., RemunanLopez, C., VilaJato, J.L., Alonso, M.J. Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polymer Sci 1997, 63(1): 125-32.
32. Lang, J.C. Ocular drug-delivery conventional ocular formulations. Adv Drug Deliv Rev 1995, 16(1): 39-43.
33. Meadows, D.L., Paugh, J.R., Joshi, A., Mordaunt, J. A novel method to evaluate residence time in humans using a nonpenetrating fluorescent tracer. Invest Ophthalmol Vis Sci 2002, 43(4): 1032-9.
34. Nemoto, E., Ueda, H., Akimoto, M., Natsume, H., Morimoto, Y. Ability of poly-L-arginine to enhance drug absorption into aqueous humor and vitreous body after instillation in rabbits. Biol Pharm Bull 2007, 30(9): 1768-72.
35. Pignatello, R., Bucolo, C., Puglisi, G. Ocular tolerability of Eudragit RS100 and RL100 nanosuspensions as carriers for ophthalmic controlled drug delivery. J Pharm Sci 2002, 91(12): 2636-41.
36. Bu, H.Z., Gukasyan, H.J., Goulet, L., Lou, X.J., Xiang, C., Koudriakova, T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr Drug Metab 2007, 8(2): 91-107.
37. Merodio, M., Arnedo, A., Renedo, M.J., Irache, J.M. Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties. Eur J Pharm Sci 2001, 12(3): 251-9.
38. Calvo, P., Sanchez, A., Martinez, J., Lopez, M.I., Calonge, M., Pastor, J.C., Alonso, M.J. Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A. Pharm Res 1996, 13(2): 311-5.
39. Adibkia, K., Siahi Shadbad, M.R., Nokhodchi, A. et al. Piroxicam nanoparticles for ocular delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J Drug Target 2007, 15(6): 407-16.
40. Gomez-Gaete, C., Tsapis, N., Besnard, M., Bochot, A., Fattal, E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm 2007, 331(2): 153-9.
41. Valero, J., Egea, M.A., Espina, M., Gamisans, F., Garcia, M.L. Effect of polymerization coadjuvants on nanocapsule elaboration and triamcinolone entrapment. Drug Dev Ind Pharm 1996, 22(2): 167-73.
42. Vandervoort, J., Ludwig, A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 2004, 57(2): 251-61.
43. Bucolo, C., Maltese, A., Puglisi, G., Pignatello, R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res 2002, 34(5): 319-23.
44. de Campos, A.M., Diebold, Y., Carvalho, E.L., Sanchez, A., Alonso, M.J. Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. Pharm Res 2004, 21(5): 803-10.
45. Enriquez de Salamanca, A., Diebold, Y., Calonge, M., Garcia-Vazquez, C., Callejo, S., Vila, A., Alonso, M.J. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Invest Ophthalmol Vis Sci 2006, 47(4): 1416-25.
46. Badawi, A.A., El-Laithy, H.M., El Qidra, R.K., El Mofty, H., El dally, M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 2008, 31(8): 1040-9.
47. Papadimitriou, S., Bikiaris, D., Avgoustakis, K., Karavas, E., Georgarakis, M. Chitosan nanoparticles loaded with dorzolamide and pramipexole. Carbohydr Polym 2008, 73(1): 44-54.
48. Motwani, S.K., Chopra, S., Talegaonkar, S., Kohli, K., Ahmad, F.J., Khar, R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008, 68(3): 513-25.
49. de la Fuente, M., Seijo, B., Alonso, M.J. Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. Invest Ophthalmol Vis Sci 2008, 49(5): 2016-24.
50. de la Fuente, M., Seijo, B., Alonso, M.J. Bioadhesive hyaluronan- chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue. Gene Ther 2008, 15(9): 668-76.
51. Chen, J., Patil, S., Seal, S., McGinnis, J.F. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 2006, 1(2): 142-50.
52. Patil, S., Reshetnikov, S., Haldar, M.K., Seal, S., Mallik, S. Surface-derivatized nanoceria with human carbonic anhydrase II inhibitors and fluorophores: A potential drug delivery device. J Phys Chem C 2007, 111(24): 8437-42.
53. Dagnelie, G. Psychophysical evaluation for visual prosthesis. Annu Rev Biomed Eng 2008, 10: 339-68.
54. Pan, T., Brown, J.D., Ziaie, B. An artificial nano-drainage implant (ANDI) for glaucoma treatment. Conf Proc IEEE Eng Med Biol Soc 2006, 1: 3174-7.
55. Diebold, Y., Jarrin, M., Saez, V. et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 2007, 28(8): 1553-64.
56. Kreilgaard, M. Dermal pharmacokinetics of microemulsion formulations determined by in vivo microdialysis. Pharm Res 2001, 18(3): 367-73.
57. Kreilgaard, M. Influence of microemulsions on cutaneous drug delivery. Adv Drug Deliv Rev 2002, 54(Suppl. 1): S77-98.
58. Gaudana, R., Jwala, J., Boddu, S.H., Mitra, A.K. Recent perspectives in ocular drug delivery. Pharm Res 2009, 26(5): 1197-216.
59. Patravale, V.B., Date, A.A., Kulkarni, R.M. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004, 56(7): 827-40.
60. Lawrence, M.J., Rees, G.D. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000, 45(1): 89-121.
61. Warisnoicharoen, W., Lansley, A.B., Lawrence, M.J. Nonionic oil-in-water microemulsions: the effect of oil type on phase behaviour. Int J Pharm 2000, 198(1): 7-27.
62. Chan, J., Maghraby, G.M., Craig, J.P., Alany, R.G. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 2007, 328(1): 65-71.
63. Lv, F.F., Zheng, L.Q., Tung, C.H. Phase behavior of the microemulsions and the stability of the chloramphenicol in the microemulsion-based ocular drug delivery system. Int J Pharm 2005, 301(1-2): 237-46.
64. Baydoun, L., Furrer, P., Gurny, R., Muller-Goymann, C.C. New surface-active polymers for ophthalmic formulations: evaluation of ocular tolerance. Eur J Pharm Biopharm 2004, 58(1): 169-75.
65. Vandamme, T.F. Microemulsions as ocular drug delivery systems: recent developments and future challenges. Prog Retin Eye Res 2002, 21(1): 15-34.
66. Klang, S., Abdulrazik, M., Benita, S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol 2000, 5(4): 521-32.
67. Naveh, N., Muchtar, S., Benita, S. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol 1994, 10(3): 509-20.
68. Mainardes, R.M., Silva, L.P. Drug delivery systems: past, present, and future. Curr Drug Targets 2004, 5(5): 449-55.
69. Kaur, I.P., Garg, A., Singla, A.K., Aggarwal, D. Vesicular systems in ocular drug delivery: an overview. Int J Pharm 2004, 269(1): 1-14.
70. Norley, S.G., Huang, L., Rouse, B.T. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro. J Immunol 1986, 136(2): 681-5.
71. Al-Muhammed, J., Ozer, A.Y., Ercan, M.T., Hincal, A.A. Invivo studies on dexamethasone sodium phosphate liposomes. J Microencapsul 1996, 13(3): 293-306.
72. Bochot, A., Fattal, E., Boutet, V., Deverre, J.R., Jeanny, J.C., Chacun, H., Couvreur, P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002, 43(1): 253-9.
73. Perini, G., Saettone, M.F., Carafa, M., Santucci, E., Alhaique, F. Niosomes as carriers for ophthalmic drugs: in vitro/in vivo evaluation. Boll Chim Farm 1996, 135(2): 145-6.
74. Aggarwal, D., Garg, A., Kaur, I.P. Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. J Pharm Pharmacol 2004, 56(12): 1509-17.
75. Vyas, S.P., Mysore, N., Jaitely, V., Venkatesan, N. Discoidal niosome based controlled ocular delivery of timolol maleate. Pharmazie 1998, 53(7): 466-9.
76. Quintana, A., Raczka, E., Piehler, L. et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 2002, 19(9): 1310-6.
77. Padilla De Jesus, O.L., Ihre, H.R., Gagne, L., Frechet, J.M., Szoka, F.C., Jr. Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug Chem 2002, 13(3): 453-61.
78. Ihre, H.R., Padilla De Jesus, O.L., Szoka, F.C., Jr., Frechet, J.M. Polyester dendritic systems for drug delivery applications: design, synthesis, and characterization. Bioconjug Chem 2002, 13(3): 443-52.
79. Milhem, O.M., Myles, C., McKeown, N.B., Attwood, D., D'Emanuele, A. Polyamidoamine Starburst dendrimers as solubility enhancers. Int J Pharm 2000, 197(1-2): 239-41.
80. Bhadra, D., Bhadra, S., Jain, S., Jain, N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm 2003, 257(1-2): 111-24.
81. Ooya, T., Lee, J., Park, K. Effects of ethylene glycol-based graft, star-shaped, and dendritic polymers on solubilization and controlled release of paclitaxel. J Control Release 2003, 93(2): 121-7.
82. Loftssona, T., Jarvinen, T. Cyclodextrins in ophthalmic drug delivery. Adv Drug Deliv Rev 1999, 36(1): 59-79.
83. Aktas, Y., Unlu, N., Orhan, M., Irkec, M., Hincal, A.A. Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev Ind Pharm 2003, 29(2): 223-30.
84. Loftsson, T., Jarho, P., Masson, M., Jarvinen, T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005, 2(2): 335-51.
85. Freedman, K.A., Klein, J.W., Crosson, C.E. Beta-cyclodextrins enhance bioavailability of pilocarpine. Curr Eye Res 1993, 12(7): 641-7.
86. Usayapant, A., Karara, A.H., Narurkar, M.M. Effect of 2- hydroxypropyl-beta-cyclodextrin on the ocular absorption of dexamethasone and dexamethasone acetate. Pharm Res 1991, 8(12): 1495-9.
87. Mehnert, W., Mader, K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001, 47(2-3): 165-96.
88. Muller, R.H., Mader, K., Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000, 50(1): 161-77.
89. Cavalli, R., Morel, S., Gasco, M.R., Chetoni, P., Saettone, M.F. Preparation and evaluation in-vitro of colloidal lipospheres containing pilocarpine as ion-pair. Int J Pharm 1995, 117(2): 243-6.
90. Cavalli, R., Gasco, M.R., Chetoni, P., Burgalassi, S., Saettone, M.F. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002, 238(1-2): 241-5.
91. Manjunath, K., Reddy, J.S., Venkateswarlu, V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005, 27(2): 127-44.
92. Gokce, E.H., Sandri, G., Bonferoni, M.C., Rossi, S., Ferrari, F., Guneri, T., Caramella, C. Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm 2008, 364(1): 76-86.
93. Li, X., Nie, S.F., Kong, J., Li, N., Ju, C.Y., Pan, W.S. A controlled- release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008, 363(1-2): 177-82.
94. Keck, C.M., Muller, R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006, 62(1): 3-16.
95. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003, 18(2): 113-20.
96. Muller, R.H., Jacobs, C., Kayser, O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001, 47(1): 3-19.
97. Van Eerdenbrugh, B., Froyen, L., Van Humbeeck, J., Martens, J.A., Augustijns, P., Van den Mooter, G. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion. Eur J Pharm Sci 2008, 35(1-2): 127-35.
98. Qi, H., Chen, W., Huang, C., Li, L., Chen, C., Li, W., Wu, C. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 2007, 337(1-2): 178-87.
99. Smith, A., Hunneyball, I.M. Evaluation of poly(lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 1986, 30(2-3): 215-20.
100. Kothuri, M.K., Pinnamaneni, S., Das, N.G., Das, S.K. Microparticles and nanoparticles in ocular drug delivery. In: Ophthalmic Drug Delivery Systems, 2nd Edition. A.K. Mitra (Ed.). Marcel Dekker: New York 2003, 437-66.
101. Collins, J.A., James, P.M., Levitsky, S.A., Bredenburg, C.E., Anderson, R.W., Leonard, F., Hardaway, R.M., 3rd Cyanoacrylate adhesives as topical hemostatic aids. II. Clinical use in seven combat casualties. Surgery 1969, 65(2): 260-3.
102. Grislain, L., Couvreur, P., Lenaerts, V., Roland, M., Deprezdecampeneere, D., Speiser, P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int J Pharm 1983, 15(3): 335-45.
103. Lenaerts, V., Couvreur, P., Christiaens-Leyh, D., Joiris, E., Roland, M., Rollman, B., Speiser, P. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 1984, 5(2): 65-8.
104. Tirnaksiz, F., Akkus, S., Celebi, N. Nanoemulsion as drug delivery systems. In: Colloids in Drug Delivery. M. Fanun (Ed.). CRC Press/Taylor & Francis: Boca Raton 2010, 221-44.
105. Diehl, K.A., Foley, J.D., Nealey, P.F., Murphy, C.J. Nanoscale topography modulates corneal epithelial cell migration. J Biomed Mater Res A 2005, 75(3): 603-11.
106. Liu, B.S., Yao, C.H., Hsu, S.H., Yeh, T.S., Chen, Y.S., Kao, S.T. A novel use of genipin-fixed gelatin as extracellular matrix for peripheral nerve regeneration. J Biomater Appl 2004, 19(1): 21-34.
107. Thomson, H., Lotery, A. The promise of nanomedicine for ocular disease. Nanomedicine (Lond) 2009, 4(6): 599-604.
108. Christie, J.G., Kompella, U.B. Ophthalmic light sensitive nanocarrier systems. Drug Discov Today 2008, 13(3-4): 124-34.
109. Kingsley, J.D., Dou, H., Morehead, J., Rabinow, B., Gendelman, H.E., Destache, C.J. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 2006, 1(3): 340-50.
110. Kao, H.J., Lin, H.R., Lo, Y.L., Yu, S.P. Characterization of pilocarpine- loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol 2006, 58(2): 179-86.
111. Pignatello, R., Bucolo, C., Spedalieri, G., Maltese, A., Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23(15): 3247-55.
112. Pignatello, R., Bucolo, C., Ferrara, P., Maltese, A., Puleo, A., Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 2002, 16(1-2): 53-61.
113. Pignatello, R., Ricupero, N., Bucolo, C., Maugeri, F., Maltese, A., Puglisi, G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 2006, 7(1): E27.
114. Adibkia, K., Omidi, Y., Siahi, M.R. et al. Inhibition of endotoxin- induced uveitis by methylprednisolone acetate nanosuspension in rabbits. J Ocul Pharmacol Ther 2007, 23(5): 421-32.
115. Khopade, A.J., Jain, N.K. Self assembling nanostructures for sustained ophthalmic drug delivery. Pharmazie 1995, 50(12): 812-4.
116. Giannavola, C., Bucolo, C., Maltese, A. et al. Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability. Pharm Res 2003, 20(4): 584-90.
117. Sakai, T., Kohno, H., Ishihara, T. et al. Treatment of experimental autoimmune uveoretinitis with poly(lactic acid) nanoparticles encapsulating betamethasone phosphate. Exp Eye Res 2006, 82(4): 657-63.
118. Li, V.H., Wood, R.W., Kreuter, J., Harmia, T., Robinson, J.R. Ocular drug delivery of progesterone using nanoparticles. J Microencapsul 1986, 3(3): 213-8.
119. Losa, C., Marchal-Heussler, L., Orallo, F., Vila Jato, J.L., Alonso, M.J. Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm Res 1993, 10(1): 80-7.
120. Losa, C., Calvo, P., Castro, E., Vila-Jato, J.L., Alonso, M.J. Improvement of ocular penetration of amikacin sulphate by association to poly(butylcyanoacrylate) nanoparticles. J Pharm Pharmacol 1991, 43(8): 548-52.
121. Marchalheussler, L., Maincent, P., Hoffman, M., Spittler, J., Couvreur, P. Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. Int J Pharm 1990, 58(2): 115-22.
122. Merodio, M., Irache, J.M., Valamanesh, F., Mirshahi, M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 2002, 23(7): 1587-94.
123. Zimmer, A.K., Serve, H., Kreuter, J. Evaluation of pilocarpine- loaded albumin particles as drug delivery systems for controlled delivery in the eye, I: in vitro and in vivo characterization. J Control Release 1994, 32: 57-70.
124. Marchal-Heussler, L., Sirbat, D., Hoffman, M., Maincent, P. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm Res 1993, 10(3): 386-90.
125. Calvo, P., Thomas, C., Alonso, M.J., Vilajato, J.L., Robinson, J.R. Study of the mechanism of interaction of poly(epsiloncaprolactone) nanocapsules with the cornea by confocal laser-scanning microscopy. Int J Pharm 1994, 103(3): 283-91.
126. Leucuta, S.E. The kinetics of in vitro release and the pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres. Int J Pharm 1989, 54(1): 71-8.
127. Vandamme, T.F., Brobeck, L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J Control Release 2005, 102(1): 23-38.
128. Saettone, M.F., Perini, G., Carafa, M., Santucci, E., Alhaique, F. Non-ionic surfactant vesicles as ophthalmic carriers for cyclopentolate. A preliminary evaluation. STP Pharma Sci 1996, 6: 94-8.
129. Bochot, A., Fattal, E., Gulik, A., Couarraze, G., Couvreur, P. Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharm Res 1998, 15(9): 1364-9.
130. El-Gazayerly, O.N., Hikal, A.H. Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. Int J Pharm 1997, 158(2): 121-7.
131. Khalil, R.M., et al. Pilocarpine hydrochloride liposomal ophthalmic drug delivery system. Egypt J Pharma Sci 1992, 33: 667-8.
132. Ahmed, I., Patton, T.F. Disposition of timolol and inulin in the rabbit eye following corneal versus non-corneal absorption. Int J Pharm 1987(38): 9-21.
133. Loftsson, T., Fririksdóttir, H., Thórisdóttir, S., Stefánsson, E. The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-[beta]- cyclodextrin formulations. Int J Pharm 1994, 104(2): 181-4.
134. Kristinsson, J.K., Fridriksdottir, H., Thorisdottir, S., Sigurdardottir, A.M., Stefansson, E., Loftsson, T. Dexamethasone- cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans. Invest Ophthalmol Vis Sci 1996, 37(6): 1199-203.
135. Fialho, S.L., da Silva-Cunha, A. New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin Experiment Ophthalmol 2004, 32(6): 626-32.
136. Garty, N., Lusky, M., Zalish, M., et al. Pilocarpine in submicron emulsion formulation for treatment of ocular hypertension: a phase II clinical trial. Invest Ophthalmol Vis Sci 1994, 35: 2175-86.
137. Civiale, C., Licciardi, M., Cavallaro, G., Giammona, G., Mazzone, M.G. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm 2009, 378(1-2): 177-86.
138. Attama, A.A., Reichl, S., Muller-Goymann, C.C. Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm 2008, 355(1-2): 307-13.
139. Muller, R.H., Runge, S.A., Ravelli, V., Thunemann, A.F., Mehnert, W., Souto, E.B. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008, 68(3): 535-44.